Mestres Gonzalvo Carlota, de Wit Hugo A J M, van Oijen Brigit P C, Hurkens Kim P G M, Janknegt Rob, Schols Jos M G A, Mulder Wubbo J, Verhey Frans R, Winkens Bjorn, van der Kuy Paul-Hugo M
Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Sittard, The Netherlands.
Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Heerlen, The Netherlands.
BMC Geriatr. 2017 Jan 26;17(1):35. doi: 10.1186/s12877-017-0426-3.
In the nursing home population, it is estimated that 1 in every 3 patients is polymedicated and given their considerable frailty, these patients are especially prone to adverse drug reactions. Clinical pharmacist-led medication reviews are considered successful interventions to improve medication safety in the inpatient setting. Due to the limited available evidence concerning the benefits of medication reviews performed in the nursing home setting, we propose a study aiming to demonstrate a positive effect that a clinical decision support system, as a health care intervention, may have on the target population. The primary objective of this study is to reduce the number of patients with at least one event when using the clinical decision support system compared to the regular care. These events consist of hospital referrals, delirium, falls, and/or deaths.
METHOD/DESIGN: This study is a multicentre, prospective, randomised study with a cluster group design. The randomisation will be per main nursing home physician and stratified per ward (somatic and psychogeriatric). In the intervention group the clinical decision support system will be used to screen medication list, laboratory values and medical history in order to obtain potential clinical relevant remarks. The remarks will be sent to the main physician and feedback will be provided whether the advice was followed or not. In the control group regular care will be applied.
We strongly believe that by using a clinical decision support system, medication reviews are performed in a standardised way which leads to comparable results between patients. In addition, using a clinical decision support system eliminates the time factor to perform medication reviews as the major problems related to medication, laboratory values, indications and/or established patient characteristics will be directly available. In this way, and in order to make the medication review process complete, consultation within healthcare professionals and/or the patient itself will be time effective and the medication surveillance could be performed around the clock.
The Netherlands National Trial Register NTR5165 . Registered 2nd April 2015.
据估计,在养老院人群中,每3名患者就有1名使用多种药物治疗,鉴于这些患者相当虚弱,他们特别容易发生药物不良反应。临床药师主导的药物评估被认为是改善住院患者用药安全的成功干预措施。由于关于在养老院环境中进行药物评估的益处的现有证据有限,我们提出一项研究,旨在证明作为一种医疗保健干预措施的临床决策支持系统可能对目标人群产生的积极影响。本研究的主要目标是,与常规护理相比,使用临床决策支持系统时减少至少发生一次以下事件的患者数量。这些事件包括医院转诊、谵妄、跌倒和/或死亡。
方法/设计:本研究是一项多中心、前瞻性、随机分组的整群研究。随机分组将按主要养老院医生进行,并按病房(躯体病和老年精神病病房)分层。在干预组中,将使用临床决策支持系统筛查用药清单、实验室检查值和病史,以获取潜在的临床相关意见。这些意见将发送给主治医生,并反馈是否遵循了建议。在对照组中,将采用常规护理。
我们坚信,通过使用临床决策支持系统,药物评估得以以标准化方式进行,从而使患者之间的结果具有可比性。此外,使用临床决策支持系统消除了进行药物评估的时间因素,因为与用药、实验室检查值、适应症和/或既定患者特征相关的主要问题将直接可得。通过这种方式,为了使药物评估过程完整,医疗专业人员和/或患者自身之间的会诊将更加高效,并且可以全天候进行药物监测。
荷兰国家试验注册库NTR5165。于2015年4月2日注册。